Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Central Bank of the Republic of Turkey (CBRT) said it has decided to resume one-week repo auctions.
2026-08-24
Central Bank of the Republic of Turkey (CBRT) said it has decided to resume one-week repo auctions.
Back
Other News
2026-08-23
According to Saudi satellite television: Sources indicate that Iraq has shifted its rhetoric from "weapons monopoly" to "weapons regulation." The government committee responsible for inventorying the weapons is still in discussions with factions that
According to Saudi satellite television: Sources indicate that Iraq has shifted its rhetoric from "weapons monopoly" to "weapons regulation." The government committee responsible for inventorying the weapons is still in discussions with factions that refuse to hand over their weapons.
2026-08-23
According to Politico, President Trump's promise to make expensive new weight-loss drugs widely available to low-income Americans has not been fulfilled. Last year, Trump promised that states participating in his government's direct-to-consumer prici
According to Politico, President Trump's promise to make expensive new weight-loss drugs widely available to low-income Americans has not been fulfilled. Last year, Trump promised that states participating in his government's direct-to-consumer pricing program would soon have access to GLP-1 drugs, such as Wegovy and Zepbound, for obese Medicaid patients. However, nine months later, access to these drugs for Medicaid patients has been reduced. Currently, only Indiana has publicly expressed support for the program. Some states have stopped reimbursing Medicaid patients needing to lose weight for these drugs, while others are considering terminating the program. Most states interviewed indicated they would not participate. States that opted out, including Maine, New Mexico, and Oklahoma, cited budgetary pressures and concerns about the long-term financial sustainability of Trump's model. Meanwhile, they have also seen other states spending hundreds of millions of dollars more on these drugs than expected.
Chat with us
, powered by
LiveChat